Articles published by Xeris Biopharma Holdings, Inc.

< Previous 1 2 Next >
Xeris Biopharma Reports Third Quarter 2024 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris to Participate in Upcoming Investor Conferences
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Reports Second Quarter 2024 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Announces CEO Succession Plan
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris to Participate in the Jefferies Global Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Updates Its Outlook for 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Reports Third Quarter 2023 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris to Participate in the 2023 Cantor Global Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
Xeris Biopharma Reports Second Quarter 2023 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Tickers XERS
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.